{"id":622718,"date":"2022-10-27T10:02:01","date_gmt":"2022-10-27T10:02:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=622718"},"modified":"2022-10-27T10:02:01","modified_gmt":"2022-10-27T10:02:01","slug":"tolllike-receptor-agonist-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/tolllike-receptor-agonist-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight_622718.html","title":{"rendered":"Toll-Like Receptor Agonist Pipeline Assessment &#8211; FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1666850283.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Toll-Like Receptor Agonist Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1666850283.jpeg\" alt=\"Toll-Like Receptor Agonist Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Toll-Like Receptor Agonist Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &lsquo;<strong>Toll-Like Receptor Agonist Pipeline Insight 2022&rsquo;<\/strong> report provides comprehensive global coverage of available, marketed, and pipeline toll-like receptor agonist therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the toll-like receptor agonist pipeline domain.<\/p>\n<p style=\"text-align: justify;\">For toll-like receptor agonist emerging drugs, the toll-like receptor agonist pipeline analysis report provides a 360&deg; view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/cbf453429734d3d9f63dfba41f262090.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>To know more in detail about the Toll-Like Receptor Agonist pipeline report offerings, click here @ <\/em><\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/toll-like-receptor-agonist-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong><em>Toll-Like Receptor Agonist Pipeline Insight<\/em><\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the&nbsp;Toll-Like Receptor Agonist Pipeline&nbsp;Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Over <strong>60+<\/strong> toll-like receptor agonist pipeline therapies are in various stages of development, and their anticipated acceptance in the toll-like receptor agonist market would significantly increase market revenue.&nbsp;<\/li>\n<li>Leading toll-like receptor agonist companies developing novel drug candidates to improve the&nbsp;toll-like receptor agonist treatment landscape include <strong>InDex Pharmaceuticals, Mologen, Exicure, Birdie Biopharmaceuticals, Seven and Eight Biopharmaceuticals, Primmune Therapeutics, Pattern Pharma, Silverback Therapeutics, Hoffman-La-Roche, Ascendis Pharma, Nektar therapeutics, BioNTech, Highlight Therapeutics, PrEP Biopharm, TriSalus Life Sciences,&nbsp; Gilead Sciences, Tallac Therapeutics, Inc., ALX Oncology Holdings Inc., Checkmate Pharmaceuticals, AIM ImmunoTech, Scopus BioPharma, BrightPath Biotherapeutics, NapaJen Pharma, Ena Respiratory, Revelation Biosciences, Immune Design, Protara Therapeutics,&nbsp; Galderma, Bolt Biotherapeutics, Jiangsu Hengrui Medicine Co., Novartis, Elicio Therapeutics, Statera BioPharma, <\/strong>and others.<\/li>\n<li>Promising toll-like receptor agonist pipeline therapies in various stages of development include <strong>P2PAR-100, SBT8230, RG 6115, TransCon TLR 7\/8 agonist, NKTR-262, BNT411, BO112, PrEP-001, BDB001, Cobitolimod, Tilsotolimod, SD 101, Lefitolimod, Vesatolimod, Vidutolimod, Rintatolimod, DUET 01, NJB 834, INNA 051, Glycopyranosyl lipid adjuvant, G 100, TARA-002, RO 7020531, Resiquimod,&nbsp; BDC 1001, SHR 2150, LHC 165, PRX 034, ELI 002, IDX 9059, Entolimod, <\/strong>and others.<\/li>\n<li>In February 2022, <strong>Primmune Therapeutics<\/strong> presented interim data related to <strong>PRTX007<\/strong>, a novel, orally administered, small molecule toll-like receptor 7 (TLR7) specific agonist that is currently in Phase 1 development, at the Conference on Retroviruses and Opportunistic Infections (CROI). Oral administration of PRTX007 in this first-in-human study of healthy volunteers exhibited a favorable safety profile, rapid absorption and conversion to TLR7 agonist PRX034, and activation of the innate immune system without causing inflammation.<\/li>\n<li><strong>Pattern&rsquo;s<\/strong> lead product, <strong>P2PAR-100,<\/strong> is an immunotherapeutic that activates innate immune cells to kill cancer cells and safely activates an efficacious innate and adaptive immune response.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Request a sample and discover the recent breakthroughs happening toll-like receptor agonist pipeline landscape @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/toll-like-receptor-agonist-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Toll-Like Receptor Agonist Pipeline Report<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Toll-Like Receptor Agonist Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Toll-like receptors (TLRs) are immune sentinels that detect pathogen-associated molecular patterns (PAMPs) such as unmethylated double-stranded DNA (CpG), single-stranded RNA (ssRNA), lipoproteins, lipopolysaccharide (LPS), and flagellin. Once these microbes have passed through physical barriers such as the skin or the mucosa of the digestive tract, they are recognized by TLRs, which activate immune cell responses. In the developing embryo of Drosophila, the Toll receptor was discovered to be an essential receptor for dorso-ventral patterning. The TLR family has ten members in humans (TLR1-TLR10) and twelve in mice (TLR1-TLR9, TLR11-TLR13). TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10 are found on the cell membrane in humans, while TLR3, TLR7, TLR8, and TLR9 are found in intracellular vesicles.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Toll-Like Receptor Agonist Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Cobitolimod: InDex Pharmaceuticals<\/strong><\/p>\n<p style=\"text-align: justify;\">Cobitolimod is a first-in-class Toll-like receptor 9 (TLR9) agonist that can provide an anti-inflammatory effect locally in the large intestine, potentially causing mucosal healing and symptom relief in ulcerative colitis. In the Phase IIb study CONDUCT, cobitolimod met the primary endpoint and demonstrated an exceptional combination of efficacy and safety.<\/p>\n<p style=\"text-align: justify;\"><strong>Tilsotolimod: Idera Pharmaceuticals<\/strong><\/p>\n<p style=\"text-align: justify;\">Tilsotolimod is a synthetic Toll-like receptor 9 agonist under investigation. Tilsotolimod intramuscular injection has been shown to promote both innate (Type-I IFN, antigen presentation) and adaptive (T cells) immune activation. Tilsotolimod has received both Fast Track and Orphan Drug designation from the FDA, and it is being tested in various tumor types and combinations with various checkpoint inhibitors.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Toll-Like Receptor Agonist Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Tilsotolimod: Idera Pharmaceuticals<\/li>\n<li>Cobitolimod: InDex Pharmaceuticals<\/li>\n<li>E5564: Eisai Co Ltd<\/li>\n<li>BDB001: Seven and Eight Biopharmaceuticals<\/li>\n<li>PrEP-001: PrEP Biopharm<\/li>\n<li>BO112: Highlight Therapeutics<\/li>\n<li>BNT411: BioNTech<\/li>\n<li>NKTR-262: Nektar therapeutics<\/li>\n<li>TransCon TLR 7\/8 agonist: Ascendis Pharma<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Learn more about the toll-like receptor agonist emerging pipeline therapies @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/toll-like-receptor-agonist-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Toll-Like Receptor Agonist Clinical Trials<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Toll-Like Receptor Agonist Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>By Product Type<\/strong><\/li>\n<ul>\n<li>Monotherapy<\/li>\n<li>Combination Therapy<\/li>\n<\/ul>\n<li><strong>By Stage<\/strong><\/li>\n<ul>\n<li>Discovery<\/li>\n<li>Pre-Clinical<\/li>\n<li>Phase I<\/li>\n<li>Phase II<\/li>\n<li>Phase III<\/li>\n<li>Pre-registration<\/li>\n<\/ul>\n<li><strong>By Route of Administration<\/strong><\/li>\n<ul>\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical<\/li>\n<\/ul>\n<li><strong>By Molecule Type<\/strong><\/li>\n<ul>\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Toll-Like Receptor Agonist Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage<\/strong>:&nbsp;Global&nbsp;<\/li>\n<li><strong>Key Toll-Like Receptor Agonist Companies<\/strong>: InDex Pharmaceuticals, Mologen, Exicure, Birdie Biopharmaceuticals, Seven and Eight Biopharmaceuticals, Primmune Therapeutics, Pattern Pharma, Silverback Therapeutics, Hoffman-La-Roche, Ascendis Pharma, Nektar therapeutics, BioNTech, Highlight Therapeutics, PrEP Biopharm, TriSalus Life Sciences,&nbsp; Gilead Sciences, Tallac Therapeutics, Inc., ALX Oncology Holdings Inc., Checkmate Pharmaceuticals, AIM ImmunoTech, Scopus BioPharma, BrightPath Biotherapeutics, NapaJen Pharma, Ena Respiratory, Revelation Biosciences, Immune Design, Protara Therapeutics,&nbsp; Galderma, Bolt Biotherapeutics, Jiangsu Hengrui Medicine Co., Novartis, Elicio Therapeutics, Statera BioPharma, and others.<\/li>\n<li><strong>Key Toll-Like Receptor Agonist Pipeline Therapies<\/strong>: P2PAR-100, SBT8230, RG 6115, TransCon TLR 7\/8 agonist, NKTR-262, BNT411, BO112, PrEP-001, BDB001, Cobitolimod, Tilsotolimod, SD 101, Lefitolimod, Vesatolimod, Vidutolimod, Rintatolimod, DUET 01, NJB 834, INNA 051, Glycopyranosyl lipid adjuvant, G 100, TARA-002, RO 7020531, Resiquimod,&nbsp; BDC 1001, SHR 2150, LHC 165, PRX 034, ELI 002, IDX 9059, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Dive deep into rich insights for toll-like receptor agonist emerging therapies and assessment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/toll-like-receptor-agonist-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Toll-Like Receptor Agonist Emerging Therapies<\/a>&nbsp;<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td valign=\"top\">\n<p>1.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>2.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>3.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Toll-Like Receptor Agonist &nbsp;Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>4.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Toll-Like Receptor Agonist Pipeline Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>5.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Late Stage Products (Phase III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>6.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Mid Stage Products (Phase&nbsp; II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>7.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>8.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Preclinical Stage Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>9.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Discovery Stage Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>10.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Toll-Like Receptor Agonist Therapeutic Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>11.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>&nbsp;Inactive Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>12.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>13.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>14.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Toll-Like Receptor Agonist Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>15.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>16.<\/p>\n<\/td>\n<td valign=\"top\">\n<p>About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>For further information on the toll-like receptor agonist current pipeline therapeutics, reach out @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/toll-like-receptor-agonist-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Toll-Like Receptor Agonist Therapeutics Assessment<\/a>&nbsp;<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=tolllike-receptor-agonist-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/toll-like-receptor-agonist-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/toll-like-receptor-agonist-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/toll-like-receptor-agonist-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=tolllike-receptor-agonist-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Toll-Like Receptor Agonist Pipeline DelveInsight&rsquo;s &lsquo;Toll-Like Receptor Agonist Pipeline Insight 2022&rsquo; report provides comprehensive global coverage of available, marketed, and pipeline toll-like receptor agonist therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/tolllike-receptor-agonist-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight_622718.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,423,404],"tags":[],"class_list":["post-622718","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/622718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=622718"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/622718\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=622718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=622718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=622718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}